HWAM
RIGL icon

Hennion & Walsh Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Hennion & Walsh Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.37M Buy
90,824
+2,980
+3% +$129K 0.13% 205
2026
Q2 		$3.44M Buy
87,844
+21,602
+33% +$666K 0.1% 259
2026
Q1 		$1.79M Buy
66,242
+14,053
+27% +$472K 0.06% 373
2025
Q4 		$2.24M Buy
+52,189
New +$1.97M 0.08% 329

Other funds holding RIGL

VVP
Venture Visionary Partners Sylvania, Ohio $3.82B AUM 21.33% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TCM
Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Hennion & Walsh Asset Management's RIGL Position: Q3 2026 in Review

Hennion & Walsh Asset Management increased its Rigel Pharmaceuticals (RIGL) stake by 3.4% in Q3 2026, buying an estimated $129K and bringing the position to 90,824 shares worth $4.37M. The position accounts for 0.13% of the portfolio, ranked #205.

Hennion & Walsh Asset Management first reported a position in RIGL in Q4 2025 and has held it in 4 quarters since. 10 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.

  • Hennion & Walsh Asset Management held 90,824 shares of Rigel Pharmaceuticals worth $4.37M as of Q3 2026.
  • Hennion & Walsh Asset Management bought 2,980 Rigel Pharmaceuticals shares in Q3 2026, an estimated $129K.
  • Rigel Pharmaceuticals made up 0.13% of Hennion & Walsh Asset Management's portfolio in Q3 2026, its #205 holding.
  • Hennion & Walsh Asset Management first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 10 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.